Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

 A large registry study in the Lancet found hazards associated with use of hydroxychloroquine and chloroquine for COVID-19. Researchers compared roughly 15,000 hospitalized for COVID-19 who were given hydroxychloroquine or chloroquine with or without a second-generation macrolide with 81,000 who weren’t given these treatments. All of the hydroxychloroquine and chloroquine groups had higher rates of in-hospital mortality (16-24%) than the control group (9%). They also had higher rates of ventricular arrhythmia during hospitalization (4-8%) versus controls (0.3%). Meanwhile, the World Health Organization announced that it had temporarily halted a hydroxychloroquine trial owing to safety concerns

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext